Abstract

You have accessJournal of UrologyKidney Cancer: Basic Research & Pathophysiology I (MP39)1 Sep 2021MP39-08 GENOMIC AND METABOLIC HALLMARKS OF TCA-CYCLE-MUTANT RENAL CELL CARCINOMAS Angela Yoo, Cerise Tang, Mark Zucker, Kelly Fitzgerald, Phillip Rappold, Kate Weiss, Benjamin Freeman, Chung-Han Lee, Maria Carlo, Ritesh Kotecha, A Ari Hakimi, and Ed Reznik Angela YooAngela Yoo More articles by this author , Cerise TangCerise Tang More articles by this author , Mark ZuckerMark Zucker More articles by this author , Kelly FitzgeraldKelly Fitzgerald More articles by this author , Phillip RappoldPhillip Rappold More articles by this author , Kate WeissKate Weiss More articles by this author , Benjamin FreemanBenjamin Freeman More articles by this author , Chung-Han LeeChung-Han Lee More articles by this author , Maria CarloMaria Carlo More articles by this author , Ritesh KotechaRitesh Kotecha More articles by this author , A Ari HakimiA Ari Hakimi More articles by this author , and Ed ReznikEd Reznik More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002054.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Mutations in TCA cycle enzymes succinate dehydrogenase (SDH) and fumarate hydratase (FH) are associated with rare kidney cancers. However, the molecular features of SDH-deficient RCC (SDHRCC) and FH-deficient RCC (FHRCC) have not been well defined. Using genomic and metabolomic profiling, we aimed to define the genetic and molecular hallmarks of TCA-cycle mutant RCC. METHODS: Patients included met either immunohistochemical (loss of FH/SDH expression and/or 2-succinocysteine positivity) or molecular (biallelic loss of FH or SDHA/B/C/D/AF2) criteria for FH- or SDH- deficiency. Both germline (if available) and somatic information were integrated to determine biallelic status. Somatic variants were identified using standard clinical pipelines, and allele-specific copy number changes were studied using the FACETS algorithm. Mass-spectrometry-based metabolomics was completed on 6 samples (3 SDHRCC and 3 FHRCC). RESULTS: 37 patients were included, 26 FHRCC and 11 SDHRCC. In the germline analysis, nearly all (16/17) SDHRCC presented with a germline mutation to SDHB, whereas only 12/20 FHRCC had pathogenic FH variants. FHRCC has a significantly higher tumor mutation burden (p=0.0165, Fig 1a) and fraction of the genome that is copy-number-altered (p = 1e-04, Fig 1b) than SDHRCC. FHRCC often arises with additional somatic mutations (Fig 1c). In contrast, only 2/11 SDHRCC patients had co-occurring mutations (Fig 1d). Notably, 100% of SDHRCC presented with deletion of chromosome 1p (location of SDHB), whereas FHRCC demonstrated high but not universal loss of 1q (FH locus). Although both FH and SDH loss truncate the TCA cycle, FHRCC and SDHRCC have metabolic differences. Urea cycle metabolites such as argininosuccinate, citrulline, homocitrulline, and arginine were elevated in FHRCC tumors but not SDHRCC tumors. FHRCC also had an excess of N6-succinyladenosine compared to SDHRCC. However, SDHRCC had an elevation of acyl-carnitine compared to FHRCC, suggesting that disruption of FADH2 oxidation through Complex II/SDH may impair normal fatty acid oxidation. CONCLUSIONS: Despite a superficial similarity, FHRCC and SDHRCC represent distinct molecular entities with unique genetic and metabolic abnormalities. Source of Funding: This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 and the Bryan Bumsted fund © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e707-e707 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Angela Yoo More articles by this author Cerise Tang More articles by this author Mark Zucker More articles by this author Kelly Fitzgerald More articles by this author Phillip Rappold More articles by this author Kate Weiss More articles by this author Benjamin Freeman More articles by this author Chung-Han Lee More articles by this author Maria Carlo More articles by this author Ritesh Kotecha More articles by this author A Ari Hakimi More articles by this author Ed Reznik More articles by this author Expand All Advertisement Loading ...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.